Literature DB >> 18313937

A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics.

V Durbecq1, L Ameye, I Veys, M Paesmans, C Desmedt, N Sirtaine, C Sotiriou, C Bernard-Marty, J M Nogaret, M Piccart, D Larsimont.   

Abstract

INTRODUCTION: To investigate the influence of ageing on the incidence of breast cancer (BC) molecular subtypes, patient age at diagnosis was correlated with bio-pathological data collected retrospectively from 2723 consecutive patients diagnosed/treated at our Institute between 2000 and 2003.
METHODS: According to their bio-characteristics, 61% of the samples could be assigned to a molecular subtype: the "HER-2+", the "ER & HER2 negative" or one of the two "luminal-like" subtypes divided according to their histological grade ("A" [HER-2-/ER+/grade 1-2] and "B" [HER-2-/ER+/grade 3]). RESULTS AND
CONCLUSION: Age is highly influencing the incidence of BC molecular subtypes. Patients younger than 40 develop a statistically higher rate of high grade proliferating "HER-2" (27%) and "ER & HER2 negative" (31%) BC whereas patients older than 50 develop mostly less aggressive hormone-dependant "luminal-A" BC (>67%). Nevertheless, a significant proportion of patients older than 70 develop "luminal-B" (19%) tumours associated with high proliferation, high grade, large size and nodal invasion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313937     DOI: 10.1016/j.critrevonc.2007.12.008

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  18 in total

1.  Age-specific changes in intrinsic breast cancer subtypes: a focus on older women.

Authors:  Emily O Jenkins; Allison M Deal; Carey K Anders; Aleix Prat; Charles M Perou; Lisa A Carey; Hyman B Muss
Journal:  Oncologist       Date:  2014-08-20

Review 2.  Current targeted therapies in breast cancer: clinical applications in the elderly woman.

Authors:  Jean-Philippe Spano; Claire Falandry; Pascal Chaibi; Gilles Freyer
Journal:  Oncologist       Date:  2011-06-24

Review 3.  Early breast cancer in the older woman.

Authors:  Sonal Gandhi; Sunil Verma
Journal:  Oncologist       Date:  2011-03-17

4.  Performance of digital screening mammography among older women in the United States.

Authors:  Louise M Henderson; Ellen S O'Meara; Dejana Braithwaite; Tracy Onega
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

Review 5.  Early breast cancer in the older woman.

Authors:  Ari VanderWalde; Arti Hurria
Journal:  Clin Geriatr Med       Date:  2011-11-23       Impact factor: 3.076

Review 6.  Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents.

Authors:  Catherine Terret; Chiara Russo
Journal:  Drugs Aging       Date:  2018-02       Impact factor: 3.923

Review 7.  Prognostic factors in elderly patients with breast cancer.

Authors:  Alessandro Cappellani; Maria Di Vita; Antonio Zanghì; Andrea Cavallaro; Gaetano Piccolo; Marcello Majorana; Giuseppina Barbera; Massimiliano Berretta
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

Review 8.  Adjuvant chemotherapy for early breast cancer in the elderly.

Authors:  Mary Leung; Iulianna Shapira; Thomas Bradley; Daniel R Budman
Journal:  Curr Treat Options Oncol       Date:  2009-04-10

Review 9.  Breast cancer management in the elderly.

Authors:  M Luque; F Arranz; J F Cueva; A de Juan; P García-Teijido; L Calvo; I Peláez; A García-Palomo; J García-Mata; S Antolín; L García-Estévez; Y Fernández
Journal:  Clin Transl Oncol       Date:  2013-10-02       Impact factor: 3.405

10.  The prevalence of luminal B subtype is higher in older postmenopausal women with ER+/HER2- breast cancer and is associated with inferior outcomes.

Authors:  Matthew Mills; Casey Liveringhouse; Frank Lee; Ronica H Nanda; Kamran A Ahmed; Iman R Washington; Ram Thapa; Brooke L Fridley; Peter Blumencranz; Martine Extermann; Loretta Loftus; Lodovico Balducci; Roberto Diaz
Journal:  J Geriatr Oncol       Date:  2020-08-26       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.